To include your compound in the COVID-19 Resource Center, submit it here.

Deciphera reports data from GIST cohort of Phase I trial of DCC-2618

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported data from 57 evaluable heavily pretreated patients with gastrointestinal stromal tumors (GIST) in a Phase I

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE